CRC HT

Clinical Research Centre

Hospital Tawau
Sabah

WhoWe Are

Clinical Research Centre Hospital Tawau (CRC HTAW) have been established since May 2017 and have been officiated on 24 October 2018 by Dr. Abd Kahar Bin Abd Asis (Deputy State Health Director) on behalf of Datuk Dr. Christina Rundi (State Health Director). The establishment of Clinical Research Unit is one of the initiatives to promote research activity in the hospital staff and to improve the service through application of Evidence Based Practice. Hospital Tawau strive to provide excellence service to the patients thus to achieve that, investment into research played an important role. The establishment of clinical research unit aim to enhance clinical research activity by nurturing conducive environment and provide support to the researchers in Ministry of Health especially in the region of Tawau. Hospital Tawau also is the lead hospital for Cluster Hospital which consisted of Hospital Lahad Datu, Hospital Semporna and Hospital Kunak thus the establishment of Clinical Research Centre is very strategic in terms of geographically location for East Coast Sabah.

OurTeam

NAME	POSITION	QUALIFICATION	EMAIL
NAME	POSITION	QUALIFICATION	EMAIL
Dr. Elisa Audrey Eddiei	Head, Emergency Physician	MD (Kursk), Master of Emergency Medicine (MMed) UM	elisaeddie@gmail.com
Dr. Chua Buai Cher	Medical Officer	MD (KSMU)	buaicher@gmail.com
JT Ho Vui Chy	Staff Nurse	Diploma in Nursing	vickyhovuichyi@hotmail.com

InvestigatorsHighlight

Dr. Elisa Audrey Eddie

Head of CRC, Hospital Tawau

Email: elisaeddie@gmail.com

MD (Kursk), Master of Emergency Medicine (MMed) UM

Areas of interest: Point of Care Ultrasound in Emergency & Critical Care, Emergency Medicine

Awards and achievements:

Winner of Oral Presentation ICCEM (2017)
Excellent Service Award, Ministry of Health Malaysia (2015)
Winner for oral presentation 3rd Sabah State Emergency Updates (2012)

Dr. Elisa is an emergency physician and the current head of Clinical Research Centre of Hospital Tawau. She is also a fellow in WINFOCUS Fellowship in Emergency &Critical Care Ultrasound. Dr. Elisa has vast experience not only in her emergency medicine field as an instructor of Basic Life Support (BLS), Trauma Life Support (TLSM), and prehospital care (PHC) but she is also active in clinical research especially in the area of point of care ultrasound.

Research Highlights

Point of Care Emergency and Critical Care Ultrasound
Acute pain in emergency medicine

Recent Publications

Low-dose short infusion ketamine as adjunct to morphine for acute long bone fracture in the emergency department: a randomized controlled trial.

Lung Ultrasonography for COVID-19 Patients in Out of Hospital Settings

Cardiac A-lines in fast scan as a sign of pneumopericardium

Project Highlights

Investigator Initiated Trial/ Research (IIT/ IIR)
Industry Sponsored Research (ISR)

	MyGenom initiative: Establishing a reference genome for precision medicine in Malaysia
	Ministry of Health (MOH) Biobank, Institute for Medical Research, Ministry of Health
NMRR-23-01702-MJA	Incidence and Characteristics of Acute Kidney Injury among Hospitalized Dengue Patients
NMRR-23-02619-POU	A prospective cohort study on a novel surgical technique Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal diseases in Malaysia.
NMRR-23-02480-SGV	Prevelance Risk Factor and Etiology of onychomycosis in psoriasis patients
NMRR-22-02846-I21	Development and Validation of Usability and Satisfaction of Health Application Questionnaire (USHA)
NMRR-18-2593-43921	Epidemiology, incidence, and clinical outcomes of snake bites treated in Hospital Pulau Pinang
RSCH-23-00281-MGB	Incidence and Characteristics of Acute Kidney Injury among Hospitalized off pump and on pump CABG patients

NMRR-21-644-59445	The Malaysian Study on Hemodialysis patients SARS-Cov-2 Vaccination Immune Response: A prospective cohort study
NMRR-23-02321-TFP	Epidemiology and Clinical Characteristics of Pemphigus in a Tertiary Hospital in Penang : A 11-Year Retrospective Study
NMRR-23-00861-1N5	Factors affecting success and failure of urethroplasty surgery in male urethral strictures : Single Surgeon Center Experience
NMRR-24-00148-KX7	Evaluating The Preliminary Outcomes Of Post Thoracic Endovascular Aortic Repair In A Single Center: A Retrospective Descriptive Cross Sectional Study
NMRR-24-00047-HB7	Traumatic Aortic Valve Rupture: A Case Report
NMRR-20-2619-56326	Preoperative Haematocrit and Packed Red Blood Cell (PRBC) Transfusion during Isolated Coronary Artery Bypass Grafting (CABG) at Penang General Hospital
RSCH-23-00280-WFH	Bridging the gap between Evidence Based Practice and Nursing Care: A Prospective Analytical Cross Sectional Study
NMRR-21-02036-YOX	Changes in blood pressure after Pfizer/BioNTech SARS-Cov-2 vaccination
NMRR-15-496-25490	Use of Baclofen in Outpatient Clinic Setting
NMRR-17-3287-36091	Survival of End Stage Renal Failure patients with and without dialysis
NMRR-14-1526-23748	An open-label study of combination of Cinacalcet and active vitamin D analogue in the management of the Severe Secondary hyperthyroidism in Haemodialysis Patients
NMRR-14-1482-23731	A prospective, observational, non-inferior study to assess the effectiveness of a biosimilar epoetin alfa (Binocrit) in maintaining haemoglobin levels in stable ESRF patients on haemodialysis
NMRR-08-789-1944	Audit of CAPD peritonitis in MOH centres in Malaysia
NMRR-16-2183-33284	Prevalence and risk factor of proteinuria in Orang Asli population in Malaysia
NMRR-20-211-52663	A prospective observational study to assess the effectiveness and safety of sofosbuvir plus daclatasvir (SOF-DCV) with or without ribavirin (RBV) in chronically infected HCV patients with end-stage renal failure receiving renal replacement therapy under real-world clinical setting in Malaysia
NMRR-22-00977-CQB	Epidemiology, Clinical Features and Risk Factors for Disease Severity in Children with COVID-19
NMRR-14-950-20443	Effect of sodium rinsing fluid on blood pressure and interdialytic weight change in haemodialysis patients
NMRR-16-2033-32927	A prospective, multicenter, observational study to determine the incidence and outcome of Acute Kidney Injury among hospitalised patients in Malaysia
NMRR-12-1385-11410	Effectiveness of Propranolol in Improving Language Function in Children with Autism Spectrum Disorder
NMRR-20-1844-55868	Development and Validation of Patient Diabetes Knowledge Questionnaire (PDKQ)
NMRR-19-2518-48707	Effects of time restricted feeding on body weight and metabolic syndrome severity in the obese adults. A pilot randomized controlled trial
NMRR-18-1393-42263	Glycaemic control among diabetes patients in pharmacist managed insulin titration
NMRR-19-2066-49960	A Randomize, Double-blind, placebo-controlled study, to assess the efficacy and safety of Tocovid Suprabio 200mg in Non-alcoholic fatty liver (NAFL)
NMRR-23-00735-4MU	IMPACT OF FACIAL ACNE SCARS ON PSYCHOSOCIAL HEALTH
NMRR-24-00984-OZ9	Diffuse Alveolar Haemorrhage and Occlusive Vasculopathy Induced by Hyaluronic Acid Cosmetic Filler Injections for Breast Augmentation. A case report.
NMRR-20-1207-55463	Global Estimation of COVID-19 Infections and Related Deaths among Healthcare Workers
NMRR-19-464-46246	Prevalence and risk factors of osteoporosis in rheumatoid arthritis patients
NMRR-19-3368-51968	The risk of tuberculosis in patients on biologics for rheumatic diseases
NMRR-19-2386-47755	Incidence and Outcomes of In-Hospital Cardiac Arrest (IHCA): A 12-Month Audit in a Malaysian Tertiary Care Hospital
NMRR-18-3761-44848	Aspirin (ASA) Desensitization in Patients With Coronary Artery Disease (CAD)

NMRR-20-2951-57003	A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 with Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer (TIGIT)
NMRR-22-02070-23D	A Randomized, Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety, and Dose Response Of LYT-100 in Patients with Idiopathic Pulmonary Fibrosis (IPF)
NMRR-23-01871-OBV	A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthmas (LITHOS)
NMRR-23-00606-M4P	MASTER PROTOCOL: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
NMRR-24-00102-YRK	A Randomised, Placebo-Controlled, Double-Blind, Multi-Centre, 4-week, 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease
NMRR-24-01815-KDL	Studies of Heart & Kidney Protection with BI 690517 in combination with empagliflozin: A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease
NMRR-23-01854-V44	A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed Treatment With Osimertinib (SAFFRON)

NMRR-16-1077-30703	Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT - CONVERSION)
NMRR-16-1514-31819	A phase 3 randomized, open-label (sponsor-blind), active-controlled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
NMRR-16-2553-33457	A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (Voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis
NMRR-16-2252-33598	A 52-week open-label (sponsor-blind), randomized, active- controlled, parallel-group, multi-center study to evaluate the efficacy and safety of daprodustat compared to recombinant human erythropoietin in subjects with anemia associated with chronic kidney disease who are initiating dialysis
NMRR-17-1753-37068	A Multicenter, Multiple-dose, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide (AMG 416) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism
NMRR-17-3137-38670	A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis
NMRR-18-3256-44987	A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naive, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
NMRR-19-739-46920	FLOW - Effect of semaglutide versus placebo on the progression of renal impairment in subjects with type 2 diabetes and chronic kidney disease
NMRR-19-1288-48307	A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer
NMRR-19-1491-48537	A Phase II two-arm study to investigate tepotinib combined with osimertinib in MET amplified, advanced or metastatic non-small cell lung cancer (NSCLC) harboring activating EGFR mutations and having acquired resistance to prior osimertinib therapy.
NMRR-20-1273-54343	A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304)
NMRR-21-688-58898	A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination with Platinum+Pemetrexed Chemotherapy in Subjects with First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer
NMRR-18-1266-41897	A multicentre international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess cardio-renal outcomes in patients with chronic KIDNEY disease